

**Ipca Laboratories Limited**

Regd. Office : 48, Kandivli Industrial Estate, Kandivli (W), Mumbai 400 067

CIN : L24239MH1949PLC007837

Tel:+91 22 6647 4444, E-mail : investors@ipca.com , Website : www.ipca.com

**STATEMENT OF STANDALONE FINANCIAL RESULTS FOR THE QUARTER AND HALF YEAR ENDED SEPTEMBER 30, 2017**

Sr. No.	Particulars	Quarter Ended			Half Year Ended		(₹ Crores)
		30.09.2017	30.06.2017	30.09.2016	30.09.2017	30.09.2016	Year Ended
		(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	31.03.2017 (Audited)
I	Revenue from operations	864.29	712.96	884.41	1577.25	1739.08	3156.66
II	Other Income	11.00	6.18	6.19	17.18	11.06	22.21
III	Total Income (I+II)	<b>875.29</b>	<b>719.14</b>	<b>890.60</b>	<b>1594.43</b>	<b>1750.14</b>	<b>3178.87</b>
IV	<b>Expenses</b>						
	a) Cost of materials consumed	218.99	253.34	255.91	472.33	488.60	947.31
	b) Purchases of stock-in-trade	44.15	27.62	45.58	71.77	79.54	161.84
	c) Changes in inventories of finished goods, work-in-progress and stock-in-trade	31.89	(13.35)	18.15	18.54	64.70	(1.73)
	d) Employee benefits expense	187.21	174.66	175.98	361.87	355.09	674.93
	e) Finance costs	6.39	5.58	6.11	11.97	12.24	23.34
	f) Depreciation and amortisation expense	44.05	43.34	42.92	87.39	85.07	171.00
	g) Other expenses	233.02	249.17	253.60	482.19	495.98	943.98
	Total Expenses (IV)	765.70	740.36	798.25	1506.06	1581.22	2920.67
V	<b>Profit / (Loss) before tax (III-IV)</b>	<b>109.59</b>	<b>(21.22)</b>	<b>92.35</b>	<b>88.37</b>	<b>168.92</b>	<b>258.20</b>
VI	Tax Expense						
	Current tax	19.00	-	21.40	19.00	37.80	56.95
	Short / (Excess) provision of earlier years	-	-	-	-	-	(0.04)
	Deferred tax liability / (asset)	(5.88)	(0.97)	16.00	(6.85)	28.60	13.00
VII	<b>Profit / (Loss) for the period from continuing operations (V-VI)</b>	<b>96.47</b>	<b>(20.25)</b>	<b>54.95</b>	<b>76.22</b>	<b>102.52</b>	<b>188.29</b>
VIII	Other Comprehensive Income	(0.56)	2.61	0.72	2.05	0.03	3.78
IX	<b>Total comprehensive Income after tax (VII+VIII)</b>	<b>95.91</b>	<b>(17.64)</b>	<b>55.67</b>	<b>78.27</b>	<b>102.55</b>	<b>192.07</b>
X	Paid-up equity share capital (Face value of ₹ 2/- each)	25.24	25.24	25.24	25.24	25.24	25.24
XI	Other Equity	-	-	-	2508.93	2346.75	2449.88
XII	Net Worth	-	-	-	2534.17	2371.99	2475.12
XIII	Earnings per share (of ₹ 2/- each) (Not annualised):						
	Basic (₹)	7.64	(1.60)	4.35	6.04	8.12	14.92
	Diluted (₹)	7.64	(1.60)	4.35	6.04	8.12	14.92

SIGNED FOR IDENTIFICATION  
BY

G. M. KAPADIA & CO.  
MUMBAI.

## STATEMENT OF STANDALONE ASSETS AND LIABILITIES AS AT SEPTEMBER 30, 2017

Particulars	(₹ Crores)	
	Unaudited 30.09.2017	Audited 31.03.2017
<b>ASSETS</b>		
<b>(1) Non-current assets</b>		
(a) Property, Plant and Equipment	1,856.30	1,899.69
(b) Capital work-in-progress	57.01	62.33
(c) Goodwill	23.61	23.61
(d) Other Intangible assets	18.90	22.67
(e) Intangible assets under development	30.23	32.54
(f) Financial Assets		
(i) Investments in Subsidiary/Joint Venture/Associate	92.85	97.96
(ii) Other investments	-	0.05
(iii) Loans	107.59	96.67
(iv) Others	2.64	2.24
(g) Other non-current assets	25.03	26.26
<b>(2) Current assets</b>		
(a) Inventories	840.92	873.54
(b) Financial Assets		
(i) Investments	120.33	113.57
(ii) Trade receivables	584.92	501.98
(iii) Cash and cash equivalents	11.25	11.10
(iv) Bank Balance other than (iii) above	6.36	6.43
(v) Loans	1.91	2.08
(vi) Others	36.02	29.85
(c) Current tax assets	-	-
(d) Other current assets	232.05	165.38
<b>Total Assets</b>	<b>4,047.92</b>	<b>3,967.95</b>
<b>EQUITY AND LIABILITIES</b>		
<b>Equity</b>		
(a) Equity Share Capital	25.24	25.24
(b) Other Equity	2,508.93	2,449.88
<b>Liabilities</b>		
<b>(1) Non-current liabilities</b>		
(a) Financial Liabilities		
(i) Borrowings	263.58	351.74
(ii) Other financial liabilities	-	-
(b) Provisions	26.84	24.55
(c) Deferred tax liabilities (net)	161.79	168.64
(d) Other non-current liabilities	1.56	1.56
<b>(2) Current liabilities</b>		
(a) Financial Liabilities		
(i) Borrowings	339.88	177.30
(ii) Trade payables	416.22	449.22
(iii) Other financial liabilities	186.79	212.41
(b) Other current liabilities	33.87	36.12
(c) Provisions	71.23	66.07
(d) Current Tax Liabilities (Net)	11.99	5.22
<b>Total Equity and Liabilities</b>	<b>4,047.92</b>	<b>3,967.95</b>



SIGNED FOR IDENTIFICATION  
BY

*G. M. Kapadia*  
G. M. KAPADIA & CO.  
MUMBAI.

**Notes:**

- 1 The above unaudited financial results, as reviewed by the Audit Committee, were approved and taken on record by the Board of Directors in their meeting held on November 14, 2017.
- 2 The Auditors of the Company have carried out the limited review of the above unaudited financial results.
- 3 At the meeting of the Board of Directors of the Company held on April 25, 2017, the Company has granted 1,65,000 options under Ipca Laboratories Ltd. Employees Stock Option Scheme – 2014. Each option granted gives a right but not an obligation to the Option Grantee to apply for 1 equity share of ₹ 2/- each fully paid up of the Company at a price of ₹ 300/- per share upon completion of 1 year from the date of grant of options. The compensation cost and its accounting has been done in accordance with Ind AS - 102 - Share based payment on the basis of the fair value of the options granted over the vesting period.
- 4 In accordance with the requirements of Ind AS 18, Revenue from Operations for the quarter ended September 30, 2017 is shown net of Goods and Services Tax (GST). However, Revenue from Operations for the preceding periods are shown inclusive of Excise Duty, wherever applicable. For comparison purposes revenue excluding excise duty is given below :

Sr.No.	Particulars	Quarter Ended			Half Year Ended		(₹ Crores)
		30.09.2017	30.06.2017	30.09.2016	30.09.2017	30.09.2016	31.03.2017
A.	Total Income from operations	864.29	712.96	884.41	1,577.25	1,739.08	3,156.66
B.	Excise Duty on sales (included in other expenses)	-	10.28	13.03	10.28	25.94	47.18
C.	Total Income from operations excluding Excise duty on Sales (A-B)	864.29	702.68	871.38	1,566.97	1,713.14	3,109.48

- 5 The Company has paid the principal and interest due on non-convertible debentures on due dates. The final installment of redemption amounting to ₹ 5 crores on these debentures is due for repayment on December 12, 2017 along with interest. The Company has more than adequate asset coverage for these non-convertible debt securities issued.
- 6 CRISIL has reaffirmed the rating CRISIL AA-/Stable for the Company's Non-Convertible Debentures of ₹ 5 crores and CRISIL A1+ rating for the Company's ₹ 50 crores short term Debt.

(₹ Crores)

Sr.No.	Particulars	Half Year Ended		Year Ended
		30.09.2017	30.09.2016	31.03.2017
1	Debt service coverage ratio (DSCR) (No. of times)#	1.43	2.94	1.34
2	Interest service coverage ratio (ISCR) (No. of times)##	15.68	19.81	19.00
3	Debt - Equity ratio (No. of times)###	0.30	0.29	0.29
4	Capital Redemption Reserve / Debenture Redemption Reserve	5.26	5.26	5.26

# DSCR = [(Profit after tax before exceptional items + depreciation + interest on long term debts) / (Interest &amp; Principal repayment of long term debts during the period)]

## ISCR = [(Profit before tax + depreciation + gross interest) / Gross interest]

### Debt / Equity Ratio = Total debt / Net worth

- 8 The Company has only one reportable primary business segment viz. 'Pharmaceuticals'.
- 9 Figures for the previous period have been regrouped / re-classified to conform to the figures of the current period.

Place : Mumbai,  
Date : November 14, 2017

SIGNED FOR IDENTIFICATION  
BY  
*G.M. Kapadia*  
G. M. KAPADIA & CO.  
MUMBAI.



By Order of the Board  
For Ipca Laboratories Limited

*Premchand Godha*  
Premchand Godha  
Chairman & Managing Director  
(DIN 00012691)

## PRESS RELEASE

### Ipca Laboratories Q2FY18 Financial Results


**Mumbai, November 14, 2017:** Ipca Laboratories Limited today announced its unaudited standalone financial results for the second quarter and half year ended 30<sup>th</sup> September, 2017.

#### **Key Financials of Q2 FY18**

- Net total Income for the quarter is Rs. 875.29 crores as against Rs.877.57 crores in Q2 FY17.
- Indian formulations income up 3% at Rs. 424.73 crores.
- Exports Income down 7% at Rs. 380.01 crores.
- EBITDA margin @ 18.28% as against @ 16.11% in Q2 FY17
- Net Profit at Rs. 96.47 crores up 76%.

<b>Q2 FY18 at a glance</b>			(Rs. Crores)
Particulars	Q2 FY18	Q2 FY17	Growth
Total Income (Net of GST / Excise Duty)	875.29	877.57	-
Export Income	380.01	410.34	-7%
EBITDA	160.03	141.38	13%
EBITDA Margin	18.28%	16.11%	-
Profit before Forex (gain) / loss and tax	114.27	84.54	35%
Forex (gain) / loss	4.68	(7.81)	-
Net Profit after Forex (gain) / loss and tax	96.47	54.95	76%
Earnings per share of Rs. 2/- each (Rs.)	7.64	4.35	76%

<b>Q2 FY18 Revenue break-up</b>			(Rs. Crores)
Particulars	Q2 FY18	Q2 FY17	Growth
<b>Formulations</b>			
Domestic	424.73	413.63	3%
Exports	234.07	264.00	-11%
<b>Total Formulations</b>	<b>658.80</b>	<b>677.63</b>	<b>-3%</b>
<b>APIs</b>			
Domestic	47.85	41.31	16%
Exports	145.94	146.34	-
<b>Total APIs</b>	<b>193.79</b>	<b>187.65</b>	<b>3%</b>
<b>Grand Total</b>	<b>852.59</b>	<b>865.28</b>	<b>-1%</b>



**Ipca Laboratories Ltd.**

www.ipca.com

125, Kandivli Industrial Estate, CTS NO. 328, Kandivli (West), Mumbai 400 067, India | T: +91 22 6210 5000 F: +91 22 6210 5005

Regd. Office: 48, Kandivli Industrial Estate, Kandivli (West), Mumbai 400 067, India | T: +91 22 6647 4444 F: +91 22 2868 6613

E: ipca@ipca.com CIN: L24239MH1949PLC007837

**Key Financials of H1 FY18**


- Net Total Income down 8% at Rs. 1584.15 crores.
- Indian formulations income down 6% at Rs. 719.73 crores.
- Exports Income down 12% at Rs. 751.13 crores.
- EBITDA margin @ 11.85% as against @ 15.44% H1 FY17
- Net Profit at Rs. 76.22 crores down 26%.

H1 FY18 at a glance			(Rs. Crores)
Particulars	H1 FY18	H1 FY17	Growth
Total Income (Net of GST / Excise Duty)	1584.15	1724.20	-8%
Export Income	751.13	851.57	-12%
EBITDA	187.73	266.23	-29%
EBITDA Margin	11.85%	15.44%	-
Profit before Forex (gain) / loss and tax	88.72	169.24	-48%
Forex (gain) / loss	0.35	0.32	-
Net Profit after Forex (gain) / loss and tax	76.22	102.52	-26%
Earnings per share of Rs. 2/- each (Rs.)	6.04	8.12	-26%

H1 FY18 Revenue break-up			(Rs. Crores)
Particulars	H1 FY18	H1 FY17	Growth
<b>Formulations</b>			
Domestic	719.73	768.68	-6%
Exports	469.93	538.80	-13%
<b>Total Formulations</b>	<b>1189.66</b>	<b>1307.48</b>	<b>-9%</b>
<b>APIs</b>			
Domestic	84.06	79.07	6%
Exports	281.20	312.77	-10%
<b>Total APIs</b>	<b>365.26</b>	<b>391.84</b>	<b>-7%</b>
<b>Grand Total</b>	<b>1554.92</b>	<b>1699.32</b>	<b>-8%</b>

**About Ipca Laboratories:**

Ipca is a pharmaceutical company with a strong thrust on exports which now account for 47% of Company's income. Ipca is vertically integrated and produces finished dosage forms and active pharmaceutical ingredients.



Premchand Godha  
Chairman & Managing Director



Encl: Unaudited Standalone Financial Results

**Contact Information:**

Harish P. Kamath, Corporate Counsel & Company Secretary at [harish.kamath@ipca.com](mailto:harish.kamath@ipca.com) or on +91-22- 6210 6050

**Ipca Laboratories Ltd.**

[www.ipca.com](http://www.ipca.com)

125, Kandivli Industrial Estate, CTS NO. 328, Kandivli (West), Mumbai 400 067, India | T: +91 22 6210 5000 F: +91 22 6210 5005  
Regd. Office: 48, Kandivli Industrial Estate, Kandivli (West), Mumbai 400 067, India | T: +91 22 6647 4444 F: +91 22 2868 6613  
E: [ipca@ipca.com](mailto:ipca@ipca.com) CIN: L24239MH1949PLC007837